These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3412589)

  • 21. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease: long-term results of levodopa therapy.
    Pentland B; Matthews D; Mawdsley C
    Scott Med J; 1982 Oct; 27(4):284-7. PubMed ID: 7146876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Motor fluctuations in Parkinson disease: risk factors].
    Grandas F; Luquin MR; Rodríguez M; Vaamonde J; Lera G; Obeso JA
    Neurologia; 1992 May; 7(5):89-93. PubMed ID: 1389297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Problems associated with long-term levodopa treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():19-26. PubMed ID: 6587715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tiapride in levodopa-induced involuntary movements.
    Lees AJ; Lander CM; Stern GM
    J Neurol Neurosurg Psychiatry; 1979 Apr; 42(4):380-3. PubMed ID: 458486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
    Kurth MC
    Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
    Rascol O; Sabatini U; Chollet F; Fabre N; Senard JM; Montastruc JL; Celsis P; Marc-Vergnes JP; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):567-71. PubMed ID: 8201325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of current and novel levodopa formulations for the treatment of Parkinson's disease.
    Jimenez-Shahed J
    Ther Deliv; 2016; 7(3):179-91. PubMed ID: 26893250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Kostic V; Przedborski S; Flaster E; Sternic N
    Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.